Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Political Agreement on EU Clinical Trial Regulation Simplifies Rules But Misses its Initial Goal

Published: Monday, December 23, 2013
Last Updated: Sunday, December 22, 2013
Bookmark and Share
UK patients miss out the chance to participate in developing the therapies of the future.

Today's endorsement by the EU Committee of Permanent Representatives of the political agreement reached by the Lithuanian EU Council Presidency and the European Parliament, on the compromise text of the proposed EU Clinical Trials Regulation looks set to not deliver on the initial goal, set by the European Commission when it launched the process in July 2012, of making the EU a more attractive location to conduct clinical trials.

Steve Bates, BioIndustry Association (BIA) Chief Executive Officer, said: "Today's deal marks a milestone in simplifying the rules for conducting clinical trials in the EU. But, even the European Commission conceded today that it had hoped for a more ambitious approach in line with its original proposal.

"I fear that the compromise in extending the timelines for approval fails to improve the attractiveness of Europe and the UK as a location for global clinical trials. This means UK patients stand to miss out on the chance to participate in developing the therapies of the future.

"In particular increasing the timeline to over 100 days for clinical trial approvals for advanced and innovative therapies is unlikely to boost clinical research in the EU. I fear this will result in a worse position for researchers in innovative bioscience companies, medical research charities and in hospitals and academia who are developing innovative treatments, than the UK consistently achieves at present.

"This key compromise makes it harder, not easier, to deliver on the initial goal of this piece of legislation which UK MEP Glenis Willmott, the European Parliament rapporteur, defined as 'creating many skilled jobs in the UK and Europe, as well as leading to new life-saving treatments and drugs'."

However the BIA welcomes a number of the positive measures outlined in the new rules on conducting clinical trials in the EU, including:
• A streamlined application procedure via a single entry point for all clinical trials conducted in Europe
• A single authorization procedure for all clinical trials with a single decision per Member State encompassing both the regulatory and ethical/local aspects of a clinical trial assessment
• The extension of the tacit agreement principle to the whole authorization process which will give sponsors and researchers, in particular SMEs and academics, more legal certainty
• Improved conditions for conducting multinational clinical trials, which puts the Voluntary Harmonization Procedure on a legal basis
• Strengthened rules on the protection of patients and informed consent
• More transparency on the conduct and results of the clinical trial

The political agreement reached is subject to technical finalization and formal approval by the European Parliament at Plenary and by the Council.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Phase I Clinical Trials Insurance Guidance Published
ABPI, BIA and CCRA jointly publish guidance.
Wednesday, December 26, 2012
Academy of Medical Sciences Report: A Step in the Right Direction
The BioIndustry Association (BIA) welcomes the publication of a report by the Academy of Medical Sciences (AMS) which recommends urgent changes to the regulation and governance of health research in the UK.
Tuesday, January 11, 2011
Industry Concerns Over Human Tissue Authority (HTA) Licence Fee Increases
The BioIndustry Association (BIA), the Association of British Healthcare Industries (ABHI) and the British In Vitro Diagnostics Association (BIVDA) express their grave concern that the Human Tissue Authority (HTA) intends to introduce licence fee increases of up to more than three times 2008 rates for companies using human tissue.
Tuesday, March 31, 2009
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!